ISTAROXIME-CONTAINING INTRAVENOUS FORMULATION FOR THE TREATMENT OF PRE-CARDIOGENIC SHOCK AND CARDIOGENIC SHOCK - Patent 4511040

(19)

(11)

EP 4 511 040 A1

(12)

(43)	Date of publication:
	26.02.2025 Bulletin 2025/09

(21)	Application number: 23723312.7

(22)	Date of filing: 18.04.2023

(51)

International Patent Classification (IPC):

A61K 31/5685^(2006.01)
A61P 9/04^(2006.01)

A61K 45/06^(2006.01)

(52)	Cooperative Patent Classification (CPC):
	A61K 31/5685; A61P 9/04; A61K 45/06

	C-Sets:
	A61K 31/5685, A61K 2300/00;

(86)	International application number:
	PCT/US2023/018998

(87)	International publication number:
	WO 2023/205183 (26.10.2023 Gazette 2023/43)

(84)	Designated Contracting States:
	AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR
	Designated Extension States:
	BA
	Designated Validation States:
	KH MA MD TN

(30)

Priority:

20.04.2022 US 202263332909 P

(71)	Applicant: Windtree Therapeutics, Inc.
	Warrington, PA 18976 (US)

(72)	Inventor:
	SIMONSON, Steven Kennett Square, Pennsylvania 19348 (US)

(74)	Representative: Plougmann Vingtoft a/s
	Strandvejen 70 2900 Hellerup 2900 Hellerup (DK)

(54)	ISTAROXIME-CONTAINING INTRAVENOUS FORMULATION FOR THE TREATMENT OF PRE-CARDIOGENIC SHOCK AND CARDIOGENIC SHOCK